These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27575850)

  • 1. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
    Wentink MQ; Broxterman HJ; Lam SW; Boven E; Walraven M; Griffioen AW; Pili R; van der Vliet HJ; de Gruijl TD; Verheul HM
    Br J Cancer; 2016 Oct; 115(8):940-948. PubMed ID: 27575850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
    Gao F; Yang C
    Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating biomarkers of bevacizumab activity in patients with breast cancer.
    Denduluri N; Yang SX; Berman AW; Nguyen D; Liewehr DJ; Steinberg SM; Swain SM
    Cancer Biol Ther; 2008 Jan; 7(1):15-20. PubMed ID: 18059178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
    Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
    Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
    World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.
    Carbone C; Tamburrino A; Piro G; Boschi F; Cataldo I; Zanotto M; Mina MM; Zanini S; Sbarbati A; Scarpa A; Tortora G; Melisi D
    Anticancer Drugs; 2016 Jan; 27(1):29-40. PubMed ID: 26473526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors.
    Mahfouz N; Tahtouh R; Alaaeddine N; El Hajj J; Sarkis R; Hachem R; Raad I; Hilal G
    PLoS One; 2017; 12(6):e0179202. PubMed ID: 28594907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery.
    Li Z; Van Bergen T; Van de Veire S; Van de Vel I; Moreau H; Dewerchin M; Maudgal PC; Zeyen T; Spileers W; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5217-25. PubMed ID: 19474408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery.
    Van Bergen T; Vandewalle E; Moons L; Stalmans I
    Acta Ophthalmol; 2015 Nov; 93(7):667-78. PubMed ID: 25988844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CXCR4-dependent immunosuppressive Ly6C
    Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
    Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
    Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.